DNA Patents May Not Be Possible After All; Supreme Court Tosses Question Back To Lower Court
This article was originally published in The Pink Sheet Daily
Executive Summary
The Supreme Court orders the Federal Circuit to reconsider its decision that Myriad Genetics’ isolated BRCA genes are patentable in the wake of the high court’s ruling in Mayo v. Prometheus; BIO says second review may lead to more coherent and uniform opinion.